Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Completed · Phase 1
Conditions studied: Prostate Cancer
In brief
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given with QS21 in treating patients who have progressive prostate cancer.
Key facts
- Study ID
- NCT00003819
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 21
- Starts
- 1998-06-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2013-03-19
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.